Abstracts tagged "lymph node and rheumatoid arthritis"

Abstract Number: 967 • 2017 ACR/ARHP Annual Meeting
NF-κb-Inducing Kinase Regulates LTβR-Driven NF-κb Signaling and Inflammatory Activation of Endothelium
Paulina Kucharzewska¹, Chrissta Maracle², Jan Piet van Hamburg², Kim Jeucken², Henric Olsson¹ and Sander W. Tas³, ¹Bioscience, AstraZeneca, Göteborg, Sweden, ²2Department of Clinical Immunology & Rheumatology and Laboratory for Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ³Department of Clinical Immunology & Rheumatology and Laboratory for Experimental Immunology, ARC | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Sites of chronic inflammation, such as rheumatoid arthritis synovial tissue, are characterized by neovascularization and often contain tertiary lymphoid structures with characteristic features of…
Abstract Number: 1456 • 2016 ACR/ARHP Annual Meeting
Identification of a Unique Population of B220hi B-Cells in Inflamed Lymph Nodes (Bin) As a Potential Biomarker of Arthritic Progression in the Tumor Necrosis Factor Transgenic Mouse Model of Rheumatoid Arthritis
Megan Forney¹, Richard Bell², Edward Schwarz³ and Homaira Rahimi⁴, ¹Orthopedics, University of Rochester, Rochester, NY, ²Pathology, University of Rochester, Rochester, NY, ³Orthopedeatrics, University of Rochester, Rochester, NY, ⁴Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY
Background/Purpose: Using the tumor necrosis factor transgenic (TNF-Tg) mouse model of rheumatoid arthritis (RA), we have shown that during progression of knee synovitis, popliteal lymph…
Abstract Number: 2448 • 2014 ACR/ARHP Annual Meeting
DNA Methylation Analysis of Lymph Node Stromal Cells of Rheumatoid Arthritis Patients
Emmanuel Karouzakis¹, Caroline Ospelt¹, Janine Hähnlein², Renate E. Gay³, Paul Peter Tak⁴, Danielle Marie Gerlag⁵, Michel Neidhart¹, Steffen Gay¹ and Lisa G.M. van Baarsen², ¹Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ³Center of Experimental Rheumatology, Zurich University Hospital, Zurich, Switzerland, ⁴University of Cambridge,Cambridge and GlaxoSmithKline, Stevenage, United Kingdom, ⁵GSK,Clinical Unit Cambridge,R&D Projects Clinical Platforms & Sciences, Cambridge, United Kingdom
Background/Purpose Lymph node stromal cells (LNSC) build the scaffold that enables migration and interaction of lymphocytes in the lymph node. More recently, it has been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].